Quotient Stock

Quotient FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Quotient (QTNT) as of Aug 23, 2026 is 97.41 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 75.43 % — a change of 29.14% (higher).

FCF Conversion

97.41 %

YoY

29.14%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Quotient is 2026 97.41 % . FCF Conversion Rate (FCF/EBITDA) of Quotient was 2025 75.43 % . It decreases by 29.14% higher compared to the previous year.

The Quotient FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
85.73 USD
Jan 1, 2016
224.19 USD
Jan 1, 2017
89.84 USD
Jan 1, 2018
109.51 USD
Jan 1, 2019
76.34 USD
Jan 1, 2020
82.95 USD
Jan 1, 2021
75.43 USD
Jan 1, 2022
97.41 USD
The Quotient FCF Conversion history
YEARFCF ConversionYoY
97.41 %+29.14%
75.43 %-9.06%
82.95 %+8.66%
76.34 %-30.29%
109.51 %+21.90%
89.84 %-59.93%
224.19 %+161.49%
85.73 %-24.91%
114.18 %
Access this data via the Eulerpool API

Quotient Stock analysis

What does Quotient do? Quotient Ltd is a biopharmaceutical company headquartered in Eysins, Switzerland. The company was founded in 2007 with the aim of developing innovative technologies in the field of Personalized Medicine. This means that medications and therapies are specifically tailored to the individual needs of patients. Thanks to state-of-the-art production processes, products can be produced quickly and safely. Quotient Ltd has a unique business model based on transfusion technology. This technology allows the company to produce medications quickly and accurately. The different components of the medications are separated and then combined in the required dosage. This means that the medications can be precisely dosed and the risks of side effects minimized. A key focus of Quotient Ltd is the development of therapeutics. Personalized medicine and the fast and safe production of medications are at the center of this area. The transfusion technology enables medications to be produced quickly and flexibly, which is particularly important for rare diseases and personalized therapies. Another important area is the development of diagnostics. These enable diseases to be diagnosed quickly and safely. Based on this diagnosis, suitable therapies are then developed. Quotient Ltd also relies on transfusion technology for this, which enables fast, reliable, and flexible production of diagnostics. In addition to its developed technology and know-how, Quotient Ltd also has its own production facility. Here, all products are produced to the highest standards. The production facility covers an area of approximately 6,000 square meters. The modern facility is equipped with the latest technologies and meets the highest quality standards. Quotient Ltd offers a variety of products, with a special focus on personalized medicine and the fast and safe production of medications and diagnostics. One example is the PDA diagnostic system, which was developed for the fast and accurate diagnosis of autoimmune diseases. The MosaiQ system is another important product that enables fast and reliable production of medications. The success story of Quotient Ltd is closely linked to the development of transfusion technology. The company has succeeded in developing a technology that allows for the fast and safe production of personalized medicine. This technology has made Quotient Ltd a leading company in the field of personalized medicine worldwide. Today, Quotient Ltd employs over 700 people who are constantly working on the further development of personalized medicine and transfusion technology. Quotient is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quotient stock

FCF Conversion Rate (FCF/EBITDA) of Quotient is 97.41 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Quotient changed from 75.43 % to 97.41 %, representing a 29.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Quotient since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Quotient with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Quotient

All Key Metrics — Quotient